Search - tctmd.com

Displaying 781 - 800 of 2614

Sort: Relevancy | Date

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

News Daily News

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

November 09, 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

November 09, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

November 01, 2022

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

News Daily News

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

October 28, 2022

Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes

News Daily News

Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes

October 28, 2022

Early Data Suggest Plant-Based Foods Could Improve Outcomes in HF

News Daily News

Early Data Suggest Plant-Based Foods Could Improve Outcomes in HF

October 26, 2022

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

News Daily News

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

October 26, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.